A novel JAK inhibitor JTE‐052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents

• Published in: Experimental dermatology Vol. 27; no. 1; pp. 22 - 29
• Main Authors: Tanimoto, Atsuo, Shinozaki, Yuichi, Yamamoto, Yasuo, Katsuda, Yoshiaki, Taniai‐Riya, Eriko, Toyoda, Kaoru, Kakimoto, Kochi, Kimoto, Yukari, Amano, Wataru, Konishi, Noriko, Hayashi, Mikio
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01-01-2018
• Subjects: Animal models; Animals; Atopic dermatitis; Corticosteroids; Cyclosporine - therapeutic use; cytokine signalling; Cytokines - metabolism; Dermatitis; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - metabolism; Female; Haptens; Haptens - chemistry; Helper cells; Humans; Immunoglobulin E; Immunoglobulin E - blood; immunosuppressants; Inflammation; Inflammation - drug therapy; Inflammation - metabolism; Interleukin 23; Interleukin-23 - metabolism; Interleukin-23 Subunit p19 - metabolism; Janus Kinase Inhibitors - therapeutic use; Lymphocytes T; Male; Mast cells; Methotrexate; Methotrexate - therapeutic use; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oral administration; Psoriasis; Pyrroles - therapeutic use; Rats; Rats, Inbred BN; Rodents; Signal transduction; Skin; Skin - physiopathology; Tacrolimus; Thymic stromal lymphopoietin; Thymus; Topical application; atopic dermatitis; corticosteroids; immunosuppressants; psoriasis; cytokine signalling
• ISSN: 0906-6705; 1600-0625
• DOI: 10.1111/exd.13370

Janus kinases (JAKs) are required for several inflammatory cytokine signalling pathways and are implicated in the pathogenesis of chronic dermatitis, including atopic dermatitis and psoriasis. JAK inhibitors are therefore promising therapeutic candidates for chronic dermatitis. In this study, we evaluated the effects of the novel JAK inhibitor JTE‐052 on inflammatory responses associated with chronic dermatitis, and compared its profile with those of conventional therapeutic agents in rodent models of chronic dermatitis. JTE‐052 inhibited the Th1‐, Th2‐ and Th17‐type inflammatory responses of human T cells and mast cells in vitro. Oral administration of JTE‐052 inhibited skin inflammation in hapten‐induced chronic dermatitis in mice, associated with reduced levels of inflammatory cytokines in the skin and immunoglobulin (Ig) E in serum. In contrast, although ciclosporin partly inhibited skin inflammation, it did not reduce interleukin (IL)‐4 production in skin, and enhanced IgE production in serum. Oral administration of JTE‐052 also inhibited skin inflammation in mouse models of atopic dermatitis and psoriasis induced by a mite extract, thymic stromal lymphopoietin or IL‐23. The maximal efficacy of JTE‐052 in these dermatitis models was superior to the conventional therapeutic agents, ciclosporin and methotrexate. Topical application of JTE‐052 ointment ameliorated hapten‐induced chronic dermatitis in rats more effectively than tacrolimus ointment. Furthermore, JTE‐052 ointment did not cause the thinning of normal skin associated with topical corticosteroids. These results indicate that JTE‐052 is a promising candidate as an anti‐inflammatory drug for various types of chronic dermatitis, with a distinctly different profile from conventional therapy following either oral or topical application.